Supernus Pharmaceuticals Inc. (SUPN)
NASDAQ: SUPNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
SUPN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.51B
- Forward P/E
- 9.65
- EPS (TTM)
- -$1.92
- Dividend yield
- None
- 52-week range
- 40.51 – 59.68
- Day range
- 42.24 – 43.38
- Volume / Avg
- 459.13K / 769.62K
- Beta
- —
- Shares outstanding
- 58.22M
- Next earnings
- Nov 3, 2026
52-week range
SUPN stock today
Shares of Supernus Pharmaceuticals (SUPN) finished higher on Oct 7 at $43.05, a gain of 0.51% or $0.22 per share, versus the S&P 500's 0.22% decline. At this level, SUPN sits near the bottom of its 52-week range of $40.51 to $59.68: 27.9% below the high, set on Feb 25, 2026 and 6.3% above the low. SUPN is down 13.4% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 10.4%.
Supernus Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$1.92), so its P/E ratio is not meaningful. Supernus Pharmaceuticals's next earnings report is expected on Nov 3, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Supernus Pharmaceuticals
Company profileSupernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Jack A. Khattar M.B.A.
- Headquarters
- Rockville, MD
- Employees
- 778
- IPO year
- 2012
- Website
- supernus.com
Financial highlights
Full financialsIn fiscal 2025, Supernus Pharmaceuticals generated $719.0 million in revenue, up 8.6% from fiscal 2024, its 2nd consecutive year of revenue growth. Supernus Pharmaceuticals reported a net loss of $38.5 million, compared with net income of $73.9 million a year earlier. Gross margin was 89.6% (up from 88.2%) and operating margin -8.7%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $718.95M | $661.82M | $607.52M | $667.24M | $579.77M |
| Growth | +8.63% | +8.94% | -8.95% | +15.09% | +11.41% |
| Net income | $-38.55M | $73.86M | $1.32M | $60.71M | $53.42M |
| EPS (diluted) | $-0.68 | $1.32 | $0.02 | $1.04 | $0.98 |
Analyst forecast
ForecastConsensus (4 analysts)
none
Avg. price target
$61.75+43.44%
- Strong buy 0
- Buy 3
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 3, 2026
- EPS estimate
- $0.66
- Last reported (Q2 2026)
- Aug 3, 2026
- EPS actual vs est.
- $-1.01 vs —
SUPN news
All SUPN newsSupernus Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| HCMHUTCHMED (China) Limited ADR | 14.28 | -2.19% | $2.48B | vs SUPN |
| LQDALiquidia Corporation | 26.68 | +2.97% | $2.39B | vs SUPN |
| NRIXNurix Therapeutics Inc. | 22.73 | +0.58% | $2.36B | vs SUPN |
| IRONDisc Medicine Inc. | 61.18 | -0.76% | $2.35B | vs SUPN |
| HRMYHarmony Biosciences Holdings Inc. | 39.34 | -0.05% | $2.29B | vs SUPN |
| SLSSELLAS Life Sciences Group Inc. | 11.31 | -0.26% | $2.28B | vs SUPN |
| PGENPrecigen Inc. | 7.54 | -0.13% | $2.70B | vs SUPN |
| PBHPrestige Consumer Healthcare Inc. | 47.57 | +2.43% | $2.25B | vs SUPN |
Indexes, lists and sector
Supernus Pharmaceuticals stock FAQ
What is Supernus Pharmaceuticals's stock price today?
SUPN last traded at $43.05 as of Oct 7, 4:00 PM EDT, up 0.51% on the day. Prices are delayed at least 15 minutes.
When is Supernus Pharmaceuticals's next earnings date?
Supernus Pharmaceuticals is expected to report earnings on Tuesday, November 3, 2026. Analysts expect EPS of $0.66.
Who is Supernus Pharmaceuticals's CEO?
Mr. Jack A. Khattar M.B.A. is the chief executive officer of Supernus Pharmaceuticals Inc., which has about 778 employees.
What is the SUPN 52-week high?
The 52-week high for SUPN is $59.68 and the 52-week low is $40.51. The stock is currently 27.9% below its high.